BPC-157 vs TB-500 is a comparison of two unapproved “healing” peptides that athletes use for tendon, muscle and ligament injuries. The short answer: both speed healing in animals, neither has been proven in a controlled human trial, and in the only head-to-head study (32 rats with repaired Achilles tendons) TB-500 did better than BPC-157.[8] Both are banned in sport and neither is FDA-approved.[11][7]
BPC-157 vs TB-500 at a glance
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | 15-amino-acid peptide based on a stomach protein[2] | 7-amino-acid fragment of thymosin beta-4 (Ac-LKKTETQ)[5] |
| Proposed action | Blood vessel growth, tendon cell survival and migration[1] | Binds actin; helps cells move into wounds[6] |
| Half-life | Under 30 minutes in rats and dogs[17] | Cleared within about 6 to 10 hours in horses; no human data[7] |
| Human injury studies | 1 uncontrolled knee-pain chart review[1] | None for TB-500 itself[7] |
| Head-to-head rat tendon result | Higher strength, not statistically significant[8] | Significantly stronger, better-organized tendon[8] |
| FDA status | Not approved[7] | Not approved[7] |
| WADA 2026 | Prohibited (S0)[11] | Prohibited (S2)[11] |
How each peptide works
BPC-157 (“Body Protection Compound 157”) was developed in Croatia from a fragment of a gastric protein. A 2025 systematic review for orthopedic sports medicine summarized lab and animal data showing it increases growth hormone receptors on tendon cells, switches on blood-vessel-growth pathways and lowers inflammatory signals.[1] Its exact molecular target is still unknown.[7]
TB-500 is a short synthetic piece of thymosin beta-4, the part that binds actin, a building block of the cell’s internal skeleton. The idea is that it helps repair cells migrate into an injury.[5] TB-500 is not the same as full-length thymosin beta-4, so results for the whole protein do not automatically apply to the fragment. A peptide with the same core sequence sped skin wound repair in diabetic and aged mice.[6]
Evidence quality: animal vs human
This is the most important part of the comparison. Almost everything known about both peptides comes from animals.
BPC-157. The 2025 review found 36 studies on muscle, tendon, ligament and bone. Thirty-five were preclinical; the single human study was a retrospective review of knee injections.[1] In rats with a cut Achilles tendon, BPC-157 improved strength and tissue structure.[3] In the human chart review, 7 of 12 patients given BPC-157 alone reported knee pain relief lasting more than 6 months, measured by phone survey with no comparison group.[4][1]
TB-500. FDA’s 2026 review found no studies in which TB-500 was given to people.[7] Human trials exist only for full-length thymosin beta-4, for example an IV dosing study in healthy volunteers that found it well tolerated.[9] None tested a sports injury.
Head-to-head: the 2026 rat Achilles study
The only direct comparison came from Istanbul in 2026. Researchers cut and repaired the Achilles tendons of 32 male rats, then gave each group BPC-157 (10 mcg/kg/day), TB-500 (60 mcg/kg/day), both, or nothing, injected into the abdomen for four weeks.[8]
- Strength: both peptides raised the load the tendon could take before failing, but only TB-500 reached statistical significance.[8]
- Tissue structure: TB-500 significantly improved tendon-damage scores; BPC-157 improved them numerically but not significantly.[8]
- Combination: using both added no benefit over either alone.[8]
Eight rats per group is a small study, and a rat tendon repair is not a torn human rotator cuff. It is a signal, not an answer. For more on combining the two, see our Wolverine stack guide.
Side effects and safety
Neither peptide has proper human safety data.
- BPC-157: the small human studies reported no serious side effects but monitored little.[2] FDA described reports of injection-site reactions and an ER visit for shortness of breath, with causes unclear.[7]
- TB-500: no human safety data and no animal toxicity studies, according to FDA.[7]
- Theoretical cancer concern: BPC-157 promotes blood vessel growth, and beta-thymosins are involved in tumor cell movement, so doctors raise a theoretical risk for people with existing cancers. This has not been shown in humans.[20][19]
- Product quality: a French lab found that online “TB500” and “TB1000” products did not consistently contain what their labels said.[10] FDA’s main concern for both is immune reactions from impurities or clumped peptide.[7]
A 2026 Sports Medicine review added that rigorous human safety data are scarce and that the placebo effect, amplified by social media, may explain part of the benefit people report.[14]
Legal and sports status in 2026
- FDA: neither is approved. In July 2026, FDA staff recommended against adding either to the list of substances pharmacies may compound, but the Pharmacy Compounding Advisory Committee reportedly voted 8 to 6 in favor of each.[7][16] The vote is not binding. Our BPC-157 legal status guide tracks the details.
- WADA: BPC-157 is banned under S0 (non-approved substances) and TB-500 under S2 (growth factors), in and out of competition.[11] USADA warns athletes directly about BPC-157.[12]
- Racing: TB-500 has been a doping concern in horse racing for more than a decade, and labs developed tests for it in horse urine and plasma.[18]
For the wider rules, see our guide to peptides on the WADA prohibited list.
Which one suits which injury?
There is no evidence-based way to pick one for a particular injury. Marketing often pitches BPC-157 for gut and joint problems and TB-500 for muscle and flexibility, but those claims rest on animal work, not trials. If you are weighing either, questions to bring to a sports medicine physician include:
- Have I tried the standard treatments with good evidence for this injury, such as structured rehab, load management or surgery where needed?
- Am I subject to drug testing in my sport, school or job?
- Do I have a personal or family history of cancer?
- How would we know whether it is working, and what would make us stop?
A properly controlled human trial is coming: the University of Arkansas has registered a 30-person study of daily BPC-157 injections versus saline after rotator cuff surgery, due to start in January 2027.[15]
The verdict
On current evidence, TB-500 had the edge in the one controlled animal comparison, while BPC-157 has slightly more (but still very weak) human data. Neither has been shown to heal a sports injury in people, both carry unknown risks from unregulated products, and both will fail a drug test. Cleveland Clinic notes that because BPC-157 has not been well studied in people, its safety and side effects are unknown, and advises seeing a doctor before deciding to use it.[20]
For related comparisons, read BPC-157 vs GHK-Cu, oral vs injectable BPC-157 and peptides vs PRP, or browse the healing peptides hub.
This is general information, not medical advice.
